HIV infection is a chronic condition that remains a major global health problem, with an estimated 38.4 million people world-wide living with the infection. Antiretroviral Therapy (ART) can suppress HIV replication and significantly decrease AIDS-related mortality and improve lives for people living with HIV, but these regimens cannot eliminate HIV in the cells. Strictly adhering to lifelong ART (which is very challenging and stigmatizing) is required to maintain viral suppression, prevent resistance to ART and prevent HIV transmission. Removing the need for chronic ART treatment would revolutionize the standard of care for people living with HIV. Meeting these needs should considerably ease patients' stigma burden, lessen long-term health problems due to HIV including the effects of chronic immune activation/inflammation, and eliminate ART associated toxicity and resistance. Importantly, sustained ART-free HIV control may represent a more reliable approach to reducing HIV transmission and have a large impact on public health. Sustained ART-free immune virologic control, if continued over time, may contribute to the achievement of complete cure.
This research study will test two investigational drugs that are not approved by the Food and Drug Administration (FDA) to treat people living with HIV. The main objectives of this trial are to evaluate the effectiveness, safety and how well tolerated the 2 investigational drugs are versus placebo in people living with HIV who are on stable ART undergoing treatment interruption.
Potentially qualified participants will:
Qualified participants will: